Diabetes Across the Lifespan

Barnstable Brown Diabetes Symposium
October 27, 2017
John E. Anderson, MD

Disclosures

```
Advisory Board/Speaker's Bureau
```

Eli Lilly

Boehringer Ingelheim

Janssen

Sanofi

Astra Zeneca

Consultant

Abbott Diabetes

Merck

Intarcia


Acknowledgements

David G. Marrero, Ph.D.


Kathleen Stanley, CDE, RD, LD, MSeD

Kristie


Projecting the Future Diabetes Population: The Imperative for Change




Global Projections for the Diabetes Epidemic




Diabetes Cost (in billions)




Estimated lifetime risk of developing diabetes for individuals born in the United States in 2000



Prevalence of DM in Youth



What about Overweight and Obesity?





29.1 million with Diabetes

86 million with Prediabetes

Why are we all getting obese?

HOW DID OUR LIVES CHANGE OVER THE LAST 25 YEARS?

Etiology of Obesity: Dietary Intake



Daily caloric intake increased dramatically in the past 30 years

Increased portion sizes

 Marketplace portions are 2-8 fold larger than FDA recommendation

Increased frequency of eating out/fast food consumption

Changes in Portion Sizes.....

CHEESEBURGER

25 Years Ago



333 calories

Today



How many calories are in today's cheeseburger?

CHEESEBURGER

25 Years Ago



333 calories




Today



590 calories

COFFEE

25 Years Ago
Coffee
(with whole milk and sugar)





45 calories 8 ounces



How many calories are in today's coffee

COFFEE

25 Years Ago
Coffee
(with whole milk and sugar)

Today Mocha Coffee (with steamed whole milk and mocha syrup)



45 calories 8 ounces 350 calories 16 ounces

Calorie Difference: 305

POPCORN

25 Years Ago



270 calories5 cups

Today



Pow many calories are in today's large popcorn?

POPCORN

25 Years Ago





270 calories5 cups



630 calories 11 cups

Calorie Difference: 360

Which is Your Favorite?








أحلى الأوقات وألذ طعم














We Are Building Communities that Discourage Walking









Criteria for Diagnosing Diabetes

FPG ≥ 126 mg/dl

HgbA1C ≥ 6.5%

OGGT > 200 mg/dl at 2 HR

Glucose >200 mg/dl with typical symptoms


AACE/ACE 2010 Recommendation for Diagnosing Pre-diabetes

- **1. IFG** *FPG* **100-125** mg/dl (**5.6- 6.9** mmol/l)
- **2. IGT 140- 199** mg/dl (**7.8-11.0** mmol/l) *2-h post 75-g OGTT*
- 3. A1C 5.5–6.4% a screening test requires: Fasting glucose or GTT of 75 gr Glucola

AACE = american association of clinical endocrinologists; ACE = american council on education; OGTT = oral glucose tolerance test.

^{*}In 2008 AACE/ACE consensus position recommended that metabolic syndrome be considered a Pre DM equivalent.

Retinopathy in 5007 Adult Pima Indians by 12 Equal-sized Groups of Plasma Glucose




PG = plasma glucose; FPG = fasting plasma glucose

McCance DR, et al. *BMJ*. 1994;308(6940):1323-8; Gabir MM, et al. *Diabetes Care*. 2000;23(8):1108-12.

Why Not Define Type 2 Diabetes as: Fasting Glucose >115 mg/dl?

- "Too big a drop from 140 (old criterion)"
- "Too many people will be diagnosed"
- "We can't afford to treat so many people"
- "126 mg/dl = 7.0 mmol/l round number"
- These are hardly scientific arguments, but reflects consensus conferences


International Expert Committee Report on the Role of A1C in the Diagnosis of Diabetes



HbA1c = glycated haemoglobin; NPDR = nonproliferative diabetic retinopathy.

The International Expert Committee. *Diabetes Care*. 2009;32:1327.

Diagnosis of Diabetes?



Feasibility of Preventing Type 2 Diabetes

- There is a long period of glucose intolerance that precedes the development of diabetes
- Screening tests can identify persons at high risk
- There are safe, potentially effective interventions that can address modifiable risk factors:
 - Obesity
 - Body fat distribution
 - Physical inactivity
 - High blood glucose

Prediabetes Management


PREVENTION OF DIABETES: LIFESTYLE STUDIES

Prevention of T2D: Selected Lifestyle Modification Trials

Study	Country	N	Baseline BMI (kg/m²)	Intervention period (years)	RRR (%)	NNT
Diabetes Prevention Program	USA	3234	34.0	2.8	58	21
Diabetes Prevention Study	Finland	523	31	4	39	22
Da Qing	China	577	25.8	6	51	30

NNT, number needed to treat; RRR, relative risk reduction; T2D, type 2 diabetes.

Intensive Lifestyle Intervention Effectively Prevents Progression From IGT to T2D




^{*}Goal: 7% reduction in baseline body weight through low-calorie, low-fat diet and ≥150 min/week moderate intensity exercise.

IGT, impaired glucose tolerance; T2D, type 2 diabetes.

DPP Research Group. N Engl J Med. 2002;346:393-403.


Lifestyle Intervention More Effectively Prevents Diabetes as Populations Age



^{*}Goal: 7% reduction in baseline body weight through low-calorie, low-fat diet and ≥150 min/week moderate intensity exercise

DPP Research Group. N Engl J Med. 2002;346:393-403.

Effectiveness of Lifestyle Intervention for Diabetes Prevention Wanes as Weight Increases




^{*}Goal: 7% reduction in baseline body weight through low-calorie, low-fat diet and ≥150 min/week moderate intensity exercise .

DPP Research Group. *N Engl J Med*. 2002;346:393-403.

Cumulative Incidence of Diabetes Over 4 Years


The Finnish Diabetes Prevention Study



DBP, diastolic blood pressure; SBP, systolic blood pressure.

20-Year Cumulative T2D Incidence in Asian Patients with IGT

Da Qing Diabetes Prevention Study




IGT, impaired glucose tolerance; T2D, type 2 diabetes.

Li G, et al. Lancet. 2008;371:1783-1789.

23-Year All-Cause Mortality in Asian Patients with IGT


Da Qing Diabetes Prevention Study



IGT, impaired glucose tolerance.

23-Year Cardiovascular Mortality in Asian Patients with IGT

Da Qing Diabetes Prevention Study



IGT, impaired glucose tolerance.

Medical and Surgical Interventions Shown to Delay or Prevent T2D

Intervention	Follow-up Period	Reduction in Risk of T2D (P value vs placebo)				
Antihyperglycemic agents						
Metformin ¹	2.8 years	31% (P<0.001)				
Acarbose ²	3.3 years	25% (P=0.0015)				
Pioglitazone ³	2.4 years	72% (P<0.001)				
Rosiglitazone ⁴	3.0 years	60% (P<0.0001)				
Weight loss interventions						
Orlistat ⁵	4 years	37% (P=0.0032)				
Phentermine/topiramate ⁶	2 years	79% (P<0.05)				
Bariatric surgery ⁷	10 years	75% (P<0.001)				

^{1.} DPP Research Group. *N Engl J Med*. 2002;346:393-403. 2. STOP-NIDDM Trial Research Group. *Lancet*. 2002;359:2072-2077


^{3.} Defronzo RA, et al. *N Engl J Med.* 2011;364:1104-15. 4. DREAM Trial Investigators. *Lancet.* 2006;368:1096-1105.

^{5.} Torgerson JS, et al. Diabetes Care. 2004;27:155-161. 6. Garvey WT, et al. Diabetes Care. 2014;37:912-921.

^{7.} Sjostrom L, et al. N Engl J Med. 2004;351:2683-2693.

The Effect of Metformin on the Progression of IGT to Diabetes Mellitus






IGT, impaired glucose tolerance; RRR, relative risk reduction.


Yang W, et al. Chin J Endocrinol Metab. 2001;17:131-136.

Effect of Lifestyle Modification and Metformin on Cumulative Diabetes Incidence



Ramachandran A, et al. Diabetologia. 2006;49:289-297.


Effect of Acarbose on Reversion of IGT to NGT



IGT, impaired glucose tolerance; NGT, normal glucose tolerance; STOP-NIDDM, Study to Prevent Non-Insulin Dependent Diabetes Mellitus.

Chiasson JL, et al. Lancet. 2002;359:2072-2077.


Effect of Rosiglitazone on New-Onset Diabetes or Death in Patients with Prediabetes



DREAM, Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication.

Effect of Pioglitazone on Development of T2D in Patients with IGT

ACT NOW



ACT NOW, Actos Now for the Prevention of Diabetes; IGT, impaired glucose tolerance; T2D, type 2 diabetes.

228

218

140

87

244

24

Defronzo RA, et al. N Engl J Med. 2011;364:1104-1115.

303


262

Placebo

Pioglitazone

Effect of Lorcaserin on Progression to T2D


Proportion of BLOOM and BLOSSOM Patients With Newly Diagnosed Diabetes After 52 Weeks of Treatment



2012. Available at:

http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolic DrugsAdvisoryCommittee/UCM303200.pdf.

Effects of Phentermine/Topiramate ER on Glucose, Insulin, and Progression to T2D




NS, not significant; Phen/TPM ER, phentermine/topiramate extended release; T2D, type 2 diabetes.

Garvey WT, et al. Am J Clin Nutr. 2012;95:297-308.

Effects of Liraglutide in Obese Patients with Prediabetes


SCALE Obesity and Prediabetes (N=3731)



^{*}*P*<0.001 vs placebo.

Effect of Bariatric Surgery on Incidence of Type 2 Diabetes

Swedish Obesity Study





Diabetes Education & Prevention with a Lifestyle Intervention Offered at the YMCA

Why the Y?


- Lower Cost Programs
 - Lower cost "lay" group leaders
 - Operate to achieve cost recovery only
 - Policy to turn no person away for inability to pay

Past experience with national program scaling

Availability and Penetration

2700 Y facilities

57% of U.S.
 households are located within 3
 miles of a YMCA




DPP Lifestyle Intervention Delivered in the YMCA

- Group randomized pilot comparative effectiveness trial
- Adults living within 5 km of 2 community YMCAs
- Participants (N = 94)
 - Overweight/obese
 - High random capillary glucose + T2DM risk factors*
 - Allocated based on YMCA site for screening
- Intervention Offered group-based DPP
- Control Given basic advice & other Y programs

- Study Questions
 - Can the YMCA deliver group-based DPP?
 - Could it achieve similar weight loss to DPP?
 - Would it be less costly?

DEPLOY Weight Loss & Maintenance





CAN A COMMERCIAL PROGRAM PROVIDE AN ALTERNATIVE APPROACH?


 Leading global provider of weight management services

 Teach people to lose weight and keep it off by adopting a healthier lifestyle

 Clinically proven lifestyle program promotes healthy habits, a supportive environment, exercise, and smarter food choices

Weight Watchers Reach – U.S.

- Annually more than 1.7 million enrollments in Weight Watchers meetings and 1 million signups for WeightWatchers.com
- 25,000 meetings each week held in convenient times and locations (~5,000 in workplace)
 - 75% of members live with a 12 minute drive to a meeting
 - Open attendance no need to reserve or schedule ahead of time
- 20,000 field staff, all of whom are Lifetime Members
 - LTMs attend meetings for free as a reward when maintaining their weight goal



Study Design

- RCT with 226 subjects with diagnosed IGT
 - Wait list control
- Comparison of WW with the same self help program used in DEPLOY
- Data collected at 6, 12, and 24 months
- At 6 months, 5.7% weight loss vs. 1% in controls.
- At 12 months, 5.8% vs. 2%

The Public Health Promise

- Weight Watchers is the only at-scale provider of education behavior modification for weight management in the world, and the only potential DPP partner with
 - ➤ Brand awareness, channel access and investment to drive demand for Diabetes Prevention Programs
 - Infrastructure to fulfill demand at scale quickly
 - Experience with recruitment, training and management to deliver consistent, high quality results
 - > A built-in base of role model service providers
 - > A science-based approach that mirrors that of the DPP



Preventing Diabetes:
The National Diabetes
Prevention Program as a
Covered Benefit

Join the AMA-CDC initiative to increase the use of National Diabetes Prevention Programs

Prevent Diabetes **STAT**
















PreventDiabetesStat.org

National Diabetes Prevention Program

Based on the NIH-funded research, the CDC-approved, evidence-based National Diabetes Prevention Program aims to slow and prevent the development of Type 2 diabetes in the US population

- Lay and health professional lifestyle coaches teach in-person or virtual group classes of 8-15 participants
- Comprehensive program focused on weight loss through exercise, healthy eating and behavior modification



Examples of topics covered in core curriculum include:

- 1. Balancing calories
- 2. Problem solving/coping
- 3. Overcoming physical activity barriers
- 4. Strategies for healthy eating out
- 5. Social cues
- 6. Managing stress

Cost of the National DPP

 The cost of covering the National DPP is less than the medical claims incurred in the first year after an individual is diagnosed with diabetes:

As an intervention to prevent diabetes, the National DPP costs

 An average of \$450 per participant for a year

Payment models vary



- Diabetes costs approximately \$2,700 per individual with newly diagnosed diabetes in the first year of treatment*
- Individuals with prediabetes have a 15% to 30% chance of developing type 2 diabetes within five years[†]

^{*2009-2012} individual level data from the Truven Health MarketScan® Lab Database - a 4.4 million subsample of the Truven Health MarketScan® Treatment Pathways. MarketScan is a registered trademark of Truven Health Analytics Inc.

[†] Centers for Disease Control and Prevention. National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States, 2014. Atlanta, GA; 2014. Available at: http://www.cdc.gov/diabetes/pubs/statsreport14/national-diabetes-report-web.pdf

Availability of National DPPs

- Programs with or seeking CDC recognition are available around the country. The CDC recognition program is critical to ensure program quality and fidelity.
- Both in-person and virtual National DPPs are available.



For more information, visit cdc.gov/diabetes/prevention/recognition

Barriers

- Failure of uniform screening
 - USPSTF recommendations
 - Gaps in healthcare screening

Diabetes Fact Sheet, 2012 Gestational diabetes

- 2%–10% of pregnant women will develop gestational diabetes
 - Likely rate will be higher when using new diagnostic criteria
- Women are much more likely to get type 2 diabetes later if they have gestational diabetes
 - ➤ 5%-10% immediately after pregnancy
 - > 35%-60% within 10-20



Coverage for Diabetes Prevention

- UHG and CMS
- NPPP referral requirement
- CMS reimbursement policy (incremental)
- Current data suggest decreased efficacy
- FDA ruling on medication for prevention

Solutions??

- Uniform screening
- Universal coverage for DPP
- Treat pre diabetes as diabetes
 - ? Lower A1C threshold
 - ? Address CM risk

Continue the Conversation . . .

... With Schools

... With the enemy

... With local, state and federal government


... With third party payer

... With providers

... With employers

Think Outside the Box . . .

Kristie



Thank you